From the essiactea.com Home Page
For full info see http://www.essiactea.com
For more info see http://www.kathykeeton-cancer.com
Part 5 of 5
effect on cancer cachexia, according to Michael Kosty, M.D., an oncologist 
with
     Scripps Clinic and Research Foundation in La Jolla, California, who was 
the study's
     principal investigator, nor were differences noted between the two 
groups in
     anorexia or weight gain. Furthermore, the placebo group rated their 
quality of life
     higher than did those patients taking hydrazine sulfate, and some 
hydrazine sulfate
     patients experienced loss of sensation and motor function. "Therefore, 
the best we
     can say about this drug is that it has no effect and may even be 
deleterious," Dr.
     Kosty was quoted as saying in a summer 1992 issue of ASCO Highlights, a
     publication of the American Society of Clinical Oncology.
     Dr. Rowan Chlebowski, director of a UCLA research project on hydrazine 
sulfate,
     conservatively estimates that the drug could benefit about half a 
million cancer
     patients each year in the United States alone. His team has conducted 
many clinical
     studies of hydrazine over two decades. Dr. Chlebowski says that the 
drug's indirect
     mode of action against tumors is problematic to more cautious 
investigators. "We
     found that hydrazine sulfate was an anticachexia agent that indirectly 
induced
     antitumor responses without much toxicity. Its action is not directed at 
cancer cells
     yet it may profoundly affect them."
     Dr. Chlebowski and his colleagues at the Harbor-UCLA Medical Center in
     Torrance, California, recently found evidence that hydrazine sulfate 
added to
     conventional chemotherapy improves the nutritional status and prolongs 
the life of
     patients with non-small-cell lung cancer, especially deadly forms of the 
disease. In
     the January 1990 issue of the prestigious Journal of Clinical Oncology, 
he reports
     that earlier-stage patients have a median survival time of at least 328 
days,
     compared to 209 days for the placebo group. There is no curative therapy 
for this
     type of lung cancer, so the results, if confirmed, seem promising.
     The wasting syndrome seen in cancer patients is also a prime risk factor 
for AIDS
     patients with Kaposi's sarcoma. There is evidence that hydrazine 
sulfates capacity to
     stop cachexia may save many AIDS patients. Currently, Dr. Chlebowski is 
planning
     a study to test hydrazine sulfate as an anticachexia agent in patients 
who are infected
     with HIV and have lost weight.
     Even though hydrazine sulfate is now undergoing extensive Phase 111 
trials
     sponsored by the National Cancer Institute, resistance to this 
inexpensive, nontoxic
     chemotherapy in orthodox medical circles persists. Dr. Vincent DeVita, 
former
     director of the NCI, told a Washington Post reporter in 1988 that he 
thought
     hydrazine was a "ho-hum idea." Dr. Gold, until recently, has been frozen 
out of the
     "war on cancer." Two articles on cachexia published in July 1990 in the 
prestigious
     Cancer Research journal fail to reference any of Gold's path-breaking 
work, and
     one even denies there is any effective treatment for the wasting-away 
syndrome.
     Dr. Gold, who does not treat patients, says that the cost of hydrazine, 
at most,
     should be nominal comparable to the daily cost of insulin and other 
supplies for
     diabetics. "Until a pharmaceutical company sponsors the drug through the 
FDA, it
     will not be widely in use," he predicts, adding, "However, with the new 
studies, drug
     companies have suddenly begun to take notice of this most exemplary 
drug."
     Resources
     Syracuse Cancer Research Institute
     Presidential Plaza
     600 East Genesee Street
     Syracuse, NY 13202
     Reading Material
     The Cancer Industry: Unravelling the Politics, by Ralph W. Moss
(Reprinted with permission from the essiactea web site)
--- Maximus 2.00
---------------